Drug Profile
S 288310
Alternative Names: S-288310Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator OncoTherapy Science
- Developer OncoTherapy Science; Shionogi
- Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bladder cancer
Most Recent Events
- 05 Feb 2014 Discontinued - Phase-I/II for Bladder cancer in Asia (Parenteral)
- 11 Aug 2011 Phase I/II development is ongoing in Asia
- 17 Feb 2010 Phase-I/II clinical trials in Bladder cancer in Asia(Parenteral)